NCT04972253 2022-08-10
(BLASST)-3
Dana-Farber Cancer Institute
Phase 1 Withdrawn
Clinical Trials
3 trialsNCT02747797 2018-08-02
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
University of California, San Diego
Phase 2 Withdrawn
NCT02846766 2018-08-02
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
University of California, San Diego
Phase 2 Withdrawn